European Commission grants CLR 131 "orphan drug qualification" for treatment of Waldenstrom globulinemia

Globulinemia refers to certain cloned lymphocyte-growth diseases and plasma cell disease that lead to the excessive production of IgM monoclonal proteins.
Waldenstrom globulinemia has a unique clinical pathological manifestation, with lymphocytic lymphoma appearing in the patient's bone marrow and IgM monoclonal globulin disease (globulinemia) in the blood.
patients may experience lymph nodes and spleen immersion or monoclonal IgM-related symptoms in the blood.
biopharmaceutical company Cellectar Biosciences announced today that the European Medicines Agency (EMA) has granted CLR 131 "orphan drug eligibility" for the treatment of Waldenstrom's PythrinEmia (WM).
Caruso, President and CEO of Cellectar, said, "WM is an incurable disease whose treatment options are limited to one approved drug and multiple rescue therapies.
, the overall remission rate was 100% for 80 days of treatment with CLR 131.
supports our belief that CLR 131 can be an important treatment for WM patients.
the clinical potential of CR 131 in WM by further validating the qualification of orphan drugs."
Cellectar has launched a key trial to use CLR 131 in some cancer centers in the United States for patients with Waldenstrom globulinemia who have failed or are not responding well with Bruton tyrosine kinase inhibitors.